Trial · NCT07879924
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in emotional bias (Cambridge Neuropsychological Test Automated Battery (CANTAB) Emotional Bias task) | First measured at the baseline session (28 days within the first stimulation session), then measured at the fifth stimulation session, and finally repeated at the follow-up session (within 7 days +/- 3 days after the final, fifth stimulation session) | Difference in shift of emotional bias between participants who receive five sessions of tsTMS (tACS + TMS) and participants who receive TMS alone (the two forms of tsTMS under study will be individually compared to TMS). |
| Primary | Frequency of adverse effects and tolerability | After each of the five stimulation sessions. | Total adverse effects score derived from the participant-completed adverse effects questionnaire administered after each stimulation session. The total score combines the frequency and severity of reported adverse effects. |
| Primary | Participant experience and acceptability | Follow-up visit within 7 days (±3 days) after the fifth stimulation session | Participant perceptions of the acceptability and experience of receiving tsTMS or TMS with sham tACS and of participating in the study, assessed through a semi-structured qualitative interview. |
| Secondary | Change in task-related theta-frequency brain oscillatory activity | Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5 min and 30 min post-stimulation) within the same session. | Change in task-related theta-frequency brain oscillatory activity following neuromodulation, measured using electroencephalography (EEG). The outcome will compare changes in the fronto-midline theta activity during a working memory task between participants receiving tsTMS and those receiving TMS with sham tACS. |
| Secondary | Change in Frontal Theta Power | Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session. | Change in resting-state frontal theta power measured using EEG during eyes-open and eyes-closed conditions before and after neuromodulation. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Central Beta Power | Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session. | Change in resting-state central beta power measured using electroencephalogram (EEG) during eyes-open and eyes-closed conditions before and after neuromodulation. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Occipital Alpha Power | Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session. | Change in resting-state occipital alpha power measured using EEG during eyes-open and eyes-closed conditions before and after neuromodulation. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Subjective Cognitive Difficulties (Perceived Deficits Questionnaire for Depression, 5-item version (PDQ-5-D)) | Baseline and follow-up visit (within 7 days ±3 days after the fifth stimulation session). | Change in subjective cognitive difficulties from baseline to follow-up, assessed using the Perceived Deficits Questionnaire (PDQ-5-D). Changes following tsTMS will be compared with TMS with sham tACS. Total scores range from 0 to 20, with higher scores indicating greater perceived cognitive difficulties and lower scores indicating better subjective cognitive functioning. |
| Secondary | Change in Choice Reaction Time | Baseline and follow-up visit (within 7 days ± 3 days after the fifth stimulation session). | Change in reaction time performance from baseline to follow-up, assessed using the THINC-it Choice Reaction Time task. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Digit Symbol Substitution Test (DSST) Performance | Baseline and follow-up visit (within 7 days ± 3 days after the fifth stimulation session). | Change in cognitive performance from baseline to follow-up, assessed using the Digit Symbol Substitution Test (DSST). Changes following tsTMS will be compared with TMS with sham tACS. The score is the total number of correct symbol-digit substitutions completed during the test period. Higher scores indicate better cognitive performance and faster processing speed, while lower scores indicate poorer performance. |
| Secondary | Change in Physical Activity Levels | Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks). | Change in physical activity levels measured using the optional EmbracePlus wearable device. Activity metrics include actigraphy-derived activity measures and step count. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Gait Characteristics | Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks). | Change in gait characteristics measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Sleep Metrics | Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks). | Change in sleep-related measures recorded using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Pulse Rate | Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks). | Change in pulse rate measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Skin Temperature | Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks). | Change in skin temperature measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Electrodermal Activity | Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks). | Change in electrodermal activity measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS. |
| Secondary | Change in Respiratory Rate | Continuously from baseline assessment until the follow-up visit (approximately 1 to 5 weeks). | Change in respiratory rate measured using the optional EmbracePlus wearable device from baseline to follow-up. Changes following tsTMS will be compared with TMS with sham tACS. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07879924/registered